Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.53 |
| ▸ | PPARG | P37231 | 11/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17544332 | 1.00 | CYP11B1 (0.53) | CYP11B1CYP11B2PPARGPDE2APDE10A | |
| SCHEMBL29680837 | 0.92 | CYP11B1 (0.45) | CYP11B1CYP11B2PDE2APDE10AMAPT | |
| SCHEMBL17544140 | 0.92 | CYP11B1 (0.45) | CYP11B1CYP11B2PDE2APDE10AMAPT | |
| SCHEMBL19428531 | 0.77 | RAB9A (0.50) | CYP11B1PDE10AMAPT | |
| SCHEMBL17544206 | 0.75 | KDM4E (0.50) | CYP11B1CYP11B2MAPT | |
| SCHEMBL30402163 | 0.75 | KDM4E (0.50) | CYP11B1CYP11B2MAPT | |
| SCHEMBL17543999 | 0.75 | TSHR (0.55) | MAPT | |
| SCHEMBL29680788 | 0.75 | TSHR (0.55) | MAPT | |
| SCHEMBL10175817 | 0.73 | RAD51 (0.60) | CYP11B1CYP11B2PDE10AMAPT | |
| SCHEMBL17896686 | 0.70 | CYP11B2 (0.71) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-116655618-A | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| CN-107108534-B | Probes for imaging huntingtin | CHDI基金会股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | CYP11B1 4318/4885CYP11B2 4538/4885PPARG 3184/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | CYP11B1 4318/4885CYP11B2 4538/4885PPARG 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.